Citations

Citations to this article as recorded by  

• Novel bioactive 2‐phenyl‐4‐aminopyrimidine derivatives as EGFRDel19/T790M/C797S inhibitors for the treatment of non‐small cell lung cancer
  Shidi Xu, Zhihui Zhou, Jie He, Jiaojiao Guo, Xiaoling Huang, Yufeng An, Qingshan Pan, Shan Xu, Wufu Zhu
  Archiv der Pharmazie.2024;[Epub]     CrossRef
• Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
  Tae-Hwan Kim, Jin-Hyuk Choi, Mi Sun Ahn, Hyun Woo Lee, Seok Yun Kang, Yong Won Choi, Young Wha Koh, Seung-Soo Sheen
  BMC Cancer.2024;[Epub]     CrossRef
• A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
  Cam Phuong Pham, Thi Thai Hoa Nguyen, Anh Tu Do, Tuan Khoi Nguyen, Thi Anh Thu Hoang, Tuan Anh Le, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Van Luan Pham, Minh Hai Nguyen, Thi Huyen Trang Vo, Hung Kien Do, Ha Thanh Vu, Thi
  BMC Cancer.2024;[Epub]     CrossRef
• Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review
  Maxime Borgeaud, Kaushal Parikh, Giuseppe Luigi Banna, Floryane Kim, Timothée Olivier, Xiuning Le, Alfredo Addeo
  Journal of Thoracic Oncology.2024; 19(7): 973.     CrossRef
• Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam
  Van Luan Pham, Tuan Anh Le, Cam Phuong Pham, Thi Thai Hoa Nguyen, Anh Tu Do, Tuan Khoi Nguyen, Minh Hai Nguyen, Thi Anh Thu Hoang, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Thi Huyen Trang Vo, Hung Kien Do, Ha Thanh Vu, Thi
  Therapeutic Advances in Medical Oncology.2024;[Epub]     CrossRef
• Harnessing molecular hybridization approach to discover novel quinoline EGFR-TK inhibitors for cancer treatment
  Noha Ryad, Ayman Abo Elmaaty, Ibrahim M Ibrahim, Ali Hassan Ahmed Maghrabi, Maryam Abdulrahman Yahya Alahdal, Rasha Mohammed Saleem, Islam Zaki, Lina M A Abdel Ghany
  Future Medicinal Chemistry.2024; 16(11): 1087.     CrossRef
• Lung cancer and pregnancy
  A. L. Chernyshova, A. A. Chernyakov, Ju. M. Trushjuk, O. S. Dil, A. E. Chernyshova
  PULMONOLOGIYA.2024; 34(4): 544.     CrossRef
• Cytotoxicity and inhibitory potential of CUDC-101 in non-small cell lung cancer cells with rare EGFR L861Q mutation
  Chunhong Chu, Huixia Xu, Chenxue Liu, Xiangkai Wei, Lanxin Li, Rui Wang, Wenrui Cui, Guoliang Zhang, Chenyang Liu, Ke Wang, Lei An, Fei He
  Current Research in Toxicology.2024; 7: 100194.     CrossRef
• Design and synthesis of novel 2-(2-(4-bromophenyl)quinolin-4-yl)-1,3,4-oxadiazole derivatives as anticancer and antimicrobial candidates: in vitro and in silico studies
  Noha Ryad, Ayman Abo Elmaaty, Samy Selim, Mohammed S. Almuhayawi, Soad K. Al Jaouni, Mohamed S. Abdel-Aziz, Arwa Sultan Alqahtani, Islam Zaki, Lina M. A. Abdel Ghany
  RSC Advances.2024; 14(46): 34005.     CrossRef
• Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea
  Cliff Molife, Jae Min Cho, Jennifer Lapthorn, Min Ju Kang, Yulia D’yachkova, Sangmi Kim, Sam Colman, Saerom Kim, Agota Szende, Ji Hyun Park, Hee Kyung Ahn, Min Hee Hong, Kaisa-Leena Taipale, Hye Ryun Kim
  Drugs - Real World Outcomes.2023; 10(1): 131.     CrossRef
• Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer
  Pamela Soberanis Pina, Luis Lara-Mejía, Venecia Matias-Cruz, Feliciano Barrón, Andrés F. Cardona, Luis E. Raez, Eduardo Rios-Garcia, Oscar Arrieta
  Frontiers in Oncology.2023;[Epub]     CrossRef
• Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
  Gian Marco Leone, Saverio Candido, Alessandro Lavoro, Silvia Vivarelli, Giuseppe Gattuso, Daniela Calina, Massimo Libra, Luca Falzone
  Pharmaceutics.2023; 15(4): 1252.     CrossRef
• Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
  Vineeth Tatineni, Patrick J. O’Shea, Shreya Saxena, Atulya A. Khosla, Ahmad Ozair, Rupesh R. Kotecha, Xuefei Jia, Yasmeen Rauf, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet S. Ahluwalia
  Cancers.2023; 15(11): 3015.     CrossRef
• Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma
  Daniela Cárdenas-Fernández, Pamela Soberanis Pina, Jenny G. Turcott, Norberto Chávez-Tapia, Emilio Conde-Flores, Andrés F. Cardona, Oscar Arrieta
  Therapeutic Advances in Medical Oncology.2023;[Epub]     CrossRef
• Design and Synthesis of Novel Pyrazolopyrimidine Candidates As Promising EGFR-T790M Inhibitors and Apoptosis Inducers
  Ahmed A Gaber, Marwa Sharaky, Ayman Abo Elmaaty, Mohamed M Hammouda, Ahmed AE Mourad, Samy Y Elkhawaga, Mahmoud Mohamed Mokhtar, Amr S Abouzied, Mai AE Mourad, Ahmed A Al-Karmalawy
  Future Medicinal Chemistry.2023; 15(19): 1773.     CrossRef
• Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs
  Huang‐Chih Chang, Chin‐Chou Wang, Chia‐Cheng Tseng, Kuo‐Tung Huang, Yu‐Mu Chen, Yu‐Ping Chang, Chien‐Hao Lai, Wen‐Feng Fang, Meng‐Chih Lin, Hung‐Yi Chuang
  Thoracic Cancer.2023; 14(32): 3208.     CrossRef
• Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of real‐world evidence
  Huang‐Chih Chang, Kuo‐Tung Huang, Chia‐Cheng Tseng, Yu‐Mu Chen, Chien‐Hao Lai, Yu‐Ping Chang, Yung‐Che Chen, Hung‐Yi Chuang, Chin‐Chou Wang
  Thoracic Cancer.2023; 14(32): 3217.     CrossRef
• Pyrrolo[2,1-f][1,2,4]triazine: a promising fused heterocycle to target kinases in cancer therapy
  Sarbjit Singh, Divya Utreja, Vimal Kumar
  Medicinal Chemistry Research.2022; 31(1): 1.     CrossRef
• The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
  Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang
  Cancer Research and Treatment.2022; 54(2): 434.     CrossRef
• Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
  Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Kuo, Ping-Chih Hsu, John Chang
  Cancers.2022; 14(3): 674.     CrossRef
• Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
  John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
  Cancers.2022; 14(4): 977.     CrossRef
• Two Unusual Mutations in the Epidermal Growth Factor Receptor Gene in a Patient With Lung Adenocarcinoma
  Martin Zapata Laguado, Andrea Zuluaga, Rafael Parra Medina, Ricardo Bruges
  Cureus.2022;[Epub]     CrossRef
• Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands
  Hong-Yi Zhao, Hai-Peng Wang, Yu-Ze Mao, Hao Zhang, Minhang Xin, Xiao-Xiao Xi, Hao Lei, Shuai Mao, Dong-Hui Li, San-Qi Zhang
  Journal of Medicinal Chemistry.2022; 65(6): 4709.     CrossRef
• Cost-Effectiveness Analysis of Afatinib versus Gefitinib in Non-small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Mutation in Indonesia: Observational studies with Retrospectives
  Seftika Sari, Tri Murti Andayani, Dwi Endarti, Kartika Widayati
  Research Journal of Pharmacy and Technology.2022; : 1598.     CrossRef
• Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
  Rong Liu, Jianying Zhou, Xia Ling
  Clinical Medicine Insights: Oncology.2022;[Epub]     CrossRef
• Pharmacokinetic and Safety Comparison of 2 Afatinib Dimaleate Tablets in Healthy Chinese Volunteers Under Fasted Conditions: A Randomized, Open‐Label, 2‐Period, Single‐Dose Crossover Study
  Ping Shi, Xin Jiang, Ye Tao, Ting Li, Xin Li, Chenjing Wang, Yanping Liu, Yaping Ma, Xiaomeng Gao, Yu Cao
  Clinical Pharmacology in Drug Development.2022; 11(10): 1177.     CrossRef
• Grb2 interacts with necrosome components and is involved in rasfonin-induced necroptosis
  Bolin Hou, Haiwen Huang, Yueqian Li, Jingnan Liang, Zhijun Xi, Xuejun Jiang, Ling Liu, Erwei Li
  Cell Death Discovery.2022;[Epub]     CrossRef
• Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs
  Hong-Yi Zhao, Xiao-Xiao Xi, Minhang Xin, San-Qi Zhang
  Bioorganic Chemistry.2022; 128: 106057.     CrossRef
• Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity
  Amr Sonousi, Rasha A. Hassan, Eman O. Osman, Amr M. Abdou, Soha H. Emam
  Journal of Enzyme Inhibition and Medicinal Chemistry.2022; 37(1): 2644.     CrossRef
• Analysis of non-small cell lung cancer with miliary lung metastasis in patients harboring epidermal growth factor receptor mutations
  Ming-Hung Chang, Kuo-Hwa Chiang, Jiunn-Min Shieh, Kuo-Chen Cheng, Chung-Han Ho
  Scientific Reports.2022;[Epub]     CrossRef
• Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations
  Kartik Sehgal, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, Daniel B. Costa
  The Oncologist.2021; 26(4): 281.     CrossRef
• Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
  Cheol‐Kyu Park, Sung‐Yong Lee, Jae Cheol Lee, Chang‐Min Choi, Shin Yup Lee, Tae‐Won Jang, In‐Jae Oh, Young‐Chul Kim
  Thoracic Cancer.2021; 12(4): 444.     CrossRef
• Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells
  Boonyakorn Boonsri, Kiren Yacqub-Usman, Pakpoom Thintharua, Kyaw Zwar Myint, Thannicha Sae-Lao, Pam Collier, Chinnawut Suriyonplengsaeng, Noppadol Larbcharoensub, Brinda Balasubramanian, Simran Venkatraman, Isioma U. Egbuniwe, Dhanwant Gomez, Abhik Mukher
  Cancer Research and Treatment.2021; 53(2): 457.     CrossRef
• Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
  Sheng-Kai Liang, Li-Ta Keng, Chia-Hao Chang, Yueh-Feng Wen, Meng-Rui Lee, Ching-Yao Yang, Jann-Yuan Wang, Jen-Chung Ko, Jin-Yuan Shih, Chong-Jen Yu
  Frontiers in Oncology.2021;[Epub]     CrossRef
• Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
  Sojung Park, Sung Yong Lee, Dojin Kim, Yun Su Sim, Jeong-Seon Ryu, Juwhan Choi, Su Hwan Lee, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang
  BMC Cancer.2021;[Epub]     CrossRef
• Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study
  Burak Bilgin, Mehmet Ali Nahit Sendur, Sebnem Yucel, Emir Celik, Deniz Tataroglu Ozyukseler, Murat Ayhan, Tugba Basoglu, Aysegul Ilhan, Nadiye Akdeniz, Ahmet Gulmez, Izzet Dogan, Burak Yasin Aktas, Mustafa Gurbuz, Sinan Koca, Semra Paydas, Ali Murat Tatli
  Journal of Cancer Research and Clinical Oncology.2021; 147(7): 2145.     CrossRef
• Gefitinib reduces oocyte quality by disturbing meiotic progression
  Hong-Yong Zhang, Ying-Chun Ouyang, Jian Li, Chun-Hui Zhang, Wei Yue, Tie-Gang Meng, Heide Schatten, Qing-Yuan Sun, Wei-Ping Qian
  Toxicology.2021; 452: 152705.     CrossRef
• Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study
  Kristof Cuppens, Liesbet Lodewyckx, Ingel Demedts, Lore Decoster, Benoît Colinet, Koen Deschepper, Annelies Janssens, Daniella Galdermans, Thierry Pieters
  Drugs - Real World Outcomes.2021; 8(2): 141.     CrossRef
• Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
  Shun Lu, Jin-Yuan Shih, Tae-Won Jang, Chong-Kin Liam, Yongfeng Yu
  Advances in Therapy.2021; 38(5): 2038.     CrossRef
• PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment
  Cheng-Yu Chang, Yi-Chun Lai, Yu-Feng Wei, Chung-Yu Chen, Shih-Chieh Chang
  OncoTargets and Therapy.2021; Volume 14: 2301.     CrossRef
• Egfr Tyrosine Kinase Inhibitors for EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Outcomes in Asian Populations
  Edward S Kim, Barbara Melosky, Keunchil Park, Nobuyuki Yamamoto, James C - H Yang
  Future Oncology.2021; 17(18): 2395.     CrossRef
• The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
  Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang
  Scientific Reports.2021;[Epub]     CrossRef
• Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
  Antonio Passaro, Filippo de Marinis, Hai-Yan Tu, Konstantin K. Laktionov, Jifeng Feng, Artem Poltoratskiy, Jun Zhao, Eng Huat Tan, Maya Gottfried, Victor Lee, Dariusz Kowalski, Cheng Ta Yang, BJ Srinivasa, Laura Clementi, Tejaswini Jalikop, Dennis Chin Lu
  Frontiers in Oncology.2021;[Epub]     CrossRef
• An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
  Keunchil Park, Jin-Soo Kim, Joo-Hang Kim, Young-Chul Kim, Hoon-Gu Kim, Eun Kyung Cho, Jong-Youl Jin, Miyoung Kim, Angela Märten, Jin-Hyoung Kang
  BMC Cancer.2021;[Epub]     CrossRef
• Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea
  Taeyun Kim, Tae Won Jang, Chang Min Choi, Mi‐Hyun Kim, Sung Yong Lee, Cheol‐Kyu Park, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Chan Kwon Park, Sang Hoon Lee, Seung Hun Jang, Seong Hoon Yoon
  Cancer Medicine.2021; 10(17): 5809.     CrossRef
• Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
  Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, John Wen-Cheng Chang
  BMC Cancer.2021;[Epub]     CrossRef
• Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
  Po-Yen Chen, Chin-Chou Wang, Chien-Ning Hsu, Chung-Yu Chen
  Frontiers in Pharmacology.2021;[Epub]     CrossRef
• Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
  Filippo Papini, Janani Sundaresan, Alessandro Leonetti, Marcello Tiseo, Christian Rolfo, Godefridus J. Peters, Elisa Giovannetti
  Critical Reviews in Oncology/Hematology.2021; 166: 103454.     CrossRef
• Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer
  Hayato Yokota, Kazuhiro Sato, Sho Sakamoto, Yuji Okuda, Mariko Asano, Masahide Takeda, Katsutoshi Nakayama, Masatomo Miura
  Biology.2021; 10(10): 1054.     CrossRef
• Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
  Yamin Shu, Qilin Zhang, Xucheng He, Li Chen
  Cancer Management and Research.2021; Volume 13: 8297.     CrossRef
• Impact of Dose Reduction of Afatinib Used in Patients With Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
  Ziyu Wang, Xin Du, Ken Chen, Shanshan Li, Zhiheng Yu, Ziyang Wu, Li Yang, Dingding Chen, Wei Liu
  Frontiers in Pharmacology.2021;[Epub]     CrossRef
• EFIKASI TERAPI EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKIs) PADA KANKER PARU
  Fitri Wulandari, Widyaningrum Utami, Evieta Rohana, Wimzy Rizqy Prabhata
  Generics: Journal of Research in Pharmacy.2021;[Epub]     CrossRef
• Comparing the effectiveness of different EGFR‐TKIs in patients with EGFR mutant non–small‐cell lung cancer: A retrospective cohort study in Taiwan
  Yao‐Yu Hsieh, Wei‐Tse Fang, Yu‐Wen Lo, Yi‐Han Chen, Li‐Nien Chien
  International Journal of Cancer.2020; 147(4): 1107.     CrossRef
• Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
  James Chih-Hsin Yang, Martin Schuler, Sanjay Popat, Satoru Miura, Simon Heeke, Keunchil Park, Angela Märten, Edward S. Kim
  Journal of Thoracic Oncology.2020; 15(5): 803.     CrossRef
• Anticancer activity evaluation of indazolyl-substituted piperidin-4-yl-aminopyrimidines
  Chao Wang, Xiao-Wen Liu, Ting Xiao, Zhi-Qiang Xu, Shuang Cao, Hai-Feng Wang, Qiong-Jiao Yan, Shuang-Xi Gu, Yuan-Yuan Zhu
  Medicinal Chemistry Research.2020; 29(5): 910.     CrossRef
• Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer
  Xiao-yun Liu, Zi-tao Guo, Zhen-dong Chen, Yi-fan Zhang, Jia-lan Zhou, Yong Jiang, Qian-yu Zhao, Xing-xing Diao, Da-fang Zhong
  Acta Pharmacologica Sinica.2020; 41(10): 1366.     CrossRef
• Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives
  Giulia Sartori, Lorenzo Belluomini, Fiorella Lombardo, Alice Avancini, Ilaria Trestini, Emanuele Vita, Daniela Tregnago, Jessica Menis, Emilio Bria, Michele Milella, Sara Pilotto
  Expert Review of Anticancer Therapy.2020; 20(7): 531.     CrossRef
• Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study
  Ye Jiang, Wenli Chen, Weiguang Yu, Ning Shi, Guowei Han, Shuai Mao, Xinlei Zhang, Meiji Chen
  Journal of International Medical Research.2020;[Epub]     CrossRef
• Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry
  Kristian Brat, Monika Bratova, Jana Skrickova, Magda Barinova, Karolina Hurdalkova, Milos Pesek, Libor Havel, Leona Koubkova, Michal Hrnciarik, Jana Krejci, Ondrej Fischer, Milada Zemanova, Helena Coupkova, Martin Svaton
  Thoracic Cancer.2020; 11(11): 3346.     CrossRef
• Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
  Shouzheng Wang, Puyuan Xing, Ke Yang, Xuezhi Hao, Di Ma, Yuxin Mu, Junling Li
  Thoracic Cancer.2019; 10(6): 1461.     CrossRef
• Afatinib/gefitinib
  
  Reactions Weekly.2019; 1753(1): 17.     CrossRef
• Current Approaches in NSCLC Targeting K-RAS and EGFR
  Veronica Aran, Jasminka Omerovic
  International Journal of Molecular Sciences.2019; 20(22): 5701.     CrossRef
• Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA
  Jonathan Lim, Carl Samuelsen, Amanda Golembesky, Sulena Shrestha, Li Wang, Ingolf Griebsch
  Future Oncology.2019; 15(13): 1493.     CrossRef
• Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
  Maximilian J Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten, Tanja Cufer
  Future Oncology.2018; 14(27): 2861.     CrossRef